Special Issue "Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".

Deadline for manuscript submissions: 31 October 2022 | Viewed by 102

Special Issue Editors

Dr. Lionel Poulin
E-Mail Website
Guest Editor
U1019–UMR8204–CIIL–Center for Infection and Immunity of Lille, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France
Interests: innate; adaptive; myeloid; cancer; colon
Prof. Dr. Damya Laoui
E-Mail Website
Guest Editor
1. Laboratory for Cellular and Molecular Immunology, Vrije Universiteit Brussel, 1040 Brussels, Belgium
2. Myeloid Cell Immunology Lab, VIB Center for Inflammation Research, 1040 Brussels, Belgium
Interests: tumor; immunology

Special Issue Information

Dear Colleagues,

The goal of cancer immunotherapy is to induce regression of solid and hematological malignancies, indirectly attacking the cancer by regulating the patient’s immunity, establishing perduring antitumour memory and limiting adverse reactions. Although cancer immunotherapy is a rapidly evolving field which has provided significant improvements for cancer patients, tumour-induced immunosuppression and immunoresistance to treatment pose significant challenges. Combining conventional methods for cancer treatment such as surgery, chemotherapy and radiation therapy with improved immunotherapy approaches might overcome tumour resistance and enhance clinical efficacy. Similarly, the success of vaccine-based immunotherapy might be reinforced by other cutting-edge approaches such as immune checkpoint inhibitor, adoptive cell transfer and engineered T-cell therapy.

In this Special Issue, we want to deliberate on how to improve therapeutic cancer immunotherapies by discussing the potential problems and solutions for overcoming tumour resistance and enhancing clinical efficacy. Similarly, we would like to take advantage of novel knowledge and technologies, in order to reach the next breakthrough in cancer immunotherapy.

We warmly welcome all scientists working in these fields to submit their manuscripts to our Special Issue.

We look forward to receiving your contributions.

Dr. Lionel Poulin
Prof. Dr. Damya Laoui
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer vaccines
  • tumor antigens
  • suppression mechanism
  • immunotherapy
  • dendritic cell vaccines

Published Papers

This special issue is now open for submission.
Back to TopTop